Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion without systematic review or meta-analytic methodology
PubMed 42658049 · doi:10.1080/17425255.2026.2725917
What was done
The authors conducted a literature search using PubMed to write a narrative review and expert opinion summarizing the pharmacologic rationale, efficacy, pharmacokinetics, safety, and drug-drug interactions of phosphodiesterase type 5 (PDE5) inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). They also examined combination therapies and use in vulnerable populations.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. The authors qualitatively report that mirabegron, vibegron, and tadalafil appear safe and efficacious for treating LUTS secondary to BPH, show favorable pharmacokinetics, and can be used in combination with standard-of-care BPH medications. They note that further research is required to evaluate pharmacogenetics and utility after surgical treatment.
Why it matters
It outlines pharmacologic considerations for incorporating PDE5 inhibitors and β3-agonists as alternative or adjunctive medical therapies for aging men with BPH-related urinary symptoms.
Limits
This is a narrative review and expert opinion rather than a systematic review or meta-analysis; no search strategy, study selection criteria, risk-of-bias assessment, or sample sizes (n) are described. The abstract provides no quantitative data or specific clinical endpoints.
Cited by
- context Tadalafil was developed first as a prostate health drug before it was found to treat erectile dysfunction at higher doses.